[Skip to Content]
[Skip to Content Landing]
Views 1,448
Citations 0
Research Letter
July 28, 2020

Trends in HIV Preexposure Prophylaxis Prescribing in the United States, 2012-2018

Author Affiliations
  • 1Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville
  • 2Southern HIV and Alcohol Research Consortium (SHARC), University of Florida, Gainesville
JAMA. 2020;324(4):395-397. doi:10.1001/jama.2020.7312

The US Preventive Services Task Force recommends use of preexposure prophylaxis (PrEP) for individuals at risk of acquiring HIV.1 The Centers for Disease Control and Prevention estimated that 1.1 million US individuals might benefit from PrEP,2 but only 7% of those used it in 2016.3 Clinicians have been slow to prescribe PrEP, citing concerns regarding its effectiveness outside a clinical trial setting, unintended consequences, and ambiguity surrounding which type of clinician is best suited to prescribe PrEP.4 Using a commercial insurance database, this study examined trends in the number of persons prescribed PrEP, prescriptions for PrEP, and specialty of prescribing clinicians.